Description:

Study part: Concomitant Medications Month 7- 9. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Keywords:
Versions (1) ▾
  1. 1/24/18
Copyright Holder:
Roche
Uploaded on:

January 24, 2018

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Concomitant Medications Month 7- 9 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g

Concomitant Medications Month 7- 9

CONCOMITANT MEDICATIONS (MONTH 7 - 9)